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Abstract 
 
Embedded pragmatic trials (ePCTs) are embedded in health care systems as well as 
their data environments. For people living with dementia (PLWD), settings of care can 
be different from the general population and involve additional people whose 
information is also important. ePCT designs have the opportunity to leverage data that 
becomes available through the normal delivery of care which may be particularly 
valuable in Alzheimer’s Disease and Alzheimer’s Disease-Related Dementia given the 
complexity of case identification and diversity of settings of care. Grounded in the 
objectives of the Data and Technical Core of the newly established National Institute on 
Aging (NIA) Imbedded Pragmatic Alzheimer’s Disease and AD-Related Dementias 
Clinical Trials Collaboratory (IMPACT Collaboratory), this paper summarizes the state-
of-the-art in using existing data sources (e.g. Medicare Claims, electronic health 
records) in AD/ADRD ePCTs and approaches to integrating them in real world settings. 
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Introduction 
 
Health-system embedded pragmatic clinical trials (ePCTs) that address the needs of 
people living with dementia (PLWD) and their caregivers are critical for developing and 
disseminating evidence-based, non-pharmacological interventions. These trials create 
the opportunity to design interventions that will work in real-world patients and settings, 
but they require investigators to embrace new methods and partnerships as described 
by Mitchell et al.1 A key element of the ePCT approach is to leverage data derived from 
and integrated with the healthcare system workflow into the trial’s design, conduct, and 
dissemination. This approach allows cost-effective identification of participants and 
outcome data ascertainment. With the rise of electronic health records (EHRs) and 
focused attention on ePCTs stimulated by the National Institute of Health (NIH) 
Collaboratory, capabilities for using healthcare-generated data have been advancing. 
Yet unique issues facing PLWD necessitate innovative strategies in using healthcare-
generated data across the multiple healthcare settings targeted in Alzheimer’s Disease 
and Related Dementias (AD/ADRD) ePCTs.   
 
The unique challenges of using existing data sources to conduct ePCTs in AD/ADRD 
fall into several categories: 1) AD/ADRD are under-diagnosed2 and stigmatized 
diseases,3-5 2) caregivers often need to be identified,6 3) data must be accessed from 
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settings outside the traditional acute care medical system (e.g. primary care, nursing 
homes and assisted living), 4) patient- and caregiver-reported outcomes must be 
ascertained, and 5) measures are needed that span multiple settings (e.g. care 
transitions). Despite these challenges, opportunities exist to strengthen our ability to 
identify PLWD and their caregivers and to measure outcomes by leveraging data 
sources available through administrative data or electronic health records. These data 
are useful at multiple points in the ePCT process, including the design phase, conduct 
of the pilot and full trial, and subsequent dissemination. But careful consideration of the 
“fitness for use” of a particular data strategy is critical at all stages. This report will 
provide an overview of using healthcare data in ePCTs on which the objectives of the 
Data and Technical Core of the newly established National Institute on Aging (NIA) 
Imbedded Pragmatic Alzheimer’s Disease and AD-Related Dementias Clinical Trials 
Collaboratory (IMPACT Collaboratory) are based and serve as the groundwork our 
future work in addressing the unique data challenges in ePCTs among PLWD.  
 
Overview of Types of Data and Sources 
 
Clinical trialists are well-versed in data collection strategies for studies that directly 
recruit individual participants into intervention and control groups. These approaches 
use validated instruments for assessing participants and their outcomes, and employ 
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research staff to meticulously collect data either in-person, by phone, or through 
electronic media. The challenges of scaling this traditional approach to data collection 
can limit a trial’s size and the settings in which it can be conducted. When conducting 
an ePCT, investigators have an opportunity to reduce costs and burden by using 
existing data that have been ascertained in the course of usual clinical care (Table 1). 
These data include “administrative data,” which are generated for billing or regulatory 
purposes, and EHR data, which include structured elements (e.g. laboratory results, 
diagnostic codes, medications) and unstructured or text fields (e.g. clinical notes and 
imaging reports).  
 
These existing data can be accessed from federal sources, private payers, directly from 
specific health systems, or in some cases through intermediaries who facilitate 
collaboration with multiple healthcare systems and payers, such as the Distributed 
Research Network established NIH HCS Collaboratory 
(https://rethinkingclinicaltrials.org/nih-collaboratory-drn/). The Distributed Research 
Network implements a common data model that facilitates use of data from both 
Medicare Advantage and commercially insured individuals across multiple payers. 
PCORnet is another distributed research network funded by the Patient Centered 
Outcomes Research Institute (PCORI) that has implemented a related common data 
model based on EHR data (www.pcornet.org).  
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As the age of onset of dementia is most commonly over 65 years, data from the Centers 
for Medicare and Medicaid Services (CMS) are a particularly valuable asset to ePCTs 
for PLWD. Medicare claims from CMS include hospital, post-acute care, clinic, hospice 
and skilled nursing facility billing data. Medicare claims data have the advantage of 
being complete, as they include all Medicare beneficiaries in the healthcare setting 
whether the participants complete the trial or not, and are uniform across various 
healthcare systems. While these data have historically been available only for people 
enrolled in fee-for-service Medicare, data from Medicare Advantage are increasingly 
becoming available. In addition to claims, CMS also has “assessment data” from 
nursing homes (NHs) captured in the Minimum DataSet (MDS), and from home health 
agencies captured in the Outcome and Assessment Information Set (OASIS). CMS 
requires regular collection of these data to calculate payments and monitor quality. MDS 
and OASIS also include clinical information such as cognitive and functional status and 
behavioral issues. For example, MDS data capture standardized assessment of all 
residents in over 15,000 NHs in the US. Assessments are administered at minimum 
quarterly making the MDS a rich source of resident status over time. In addition, 
although the NH setting lags behind hospitals, 60 percent of NHs also have EHRs.7 
 
Uses of Healthcare Generated Data in ePCTs 
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Healthcare-generated data can be used at multiple stages in the ePCT process, from 
the design phase, to conduct of the pilot study and full trial, to subsequent dissemination 
(Figure 1). In the design phase, which is the main focus of the IMPACT Collaboratory, 
investigators can use existing data to identify potential participants to calculate power 
and sample size estimates. Existing data can also help in the design phase by enabling 
the identification and characterization of eligible healthcare settings, including 
considerations of representation of diverse populations. Aggregated data from 
healthcare systems are available from EHR data infrastructures; and publicly available 
data sources such as provider files available through CMS (e.g. PECOS,8 Certification 
and Survey Provider Enhanced Reports (CASPER)9); or through websites (e.g. OHSDI 
Atlas,10 ACT,11 Nursing HomeCompare (medicare.gov/nursing HomeCompare),12 
LTFocus (ltcfocus.org),13 Dartmouth Atlas14). These aggregated data can also be used 
to assure balance on key measures between clusters in each trial arm during the 
randomization process.  
 
In the process of study execution, both claims and EHRs can be used to identify specific 
participants, evaluate adherence to protocol, and measure outcomes. Using 
administrative data to measure longer term outcomes, including utilization and 
spending, is critical because it can be done long after the trial is complete without the 
This article is protected by copyright. All rights reserved.
need for direct participant contact. Finally, administrative data are useful to identify new 
sites for the next phases of implementation. 
 
Identification of PLWD from Healthcare-Generated Data 
 
One of the greatest potential advantages of using healthcare data in AD/ADRD ePCTs 
is the ability to identify eligible participants without directly assessing individual 
participant’s cognitive status. Instead, diagnoses in administrative data required for 
clinician billing can be used to identify a PLWD. Similarly, EHRs contain structured data 
elements with diagnoses populating problem and medical history lists. These diagnoses 
can be used to identify participants for ePCTs, with the major caveat that under-
diagnosis limits this approach. A recent meta-analysis estimated 60% of AD/ADRD 
cases are undiagnosed in the community.2 Studies evaluating the accuracy of claims 
diagnoses have shown good performance, but with under-ascertainment of mild disease 
in particular.15-19 Moreover, none of the algorithms for the identification of AD/ADRD in 
Medicare claims has yet been validated using ICD-10 diagnostic coding that began in 
2015. 
 
Access to EHRs that can be searched for symptoms, clinician comments, results of 
annual wellness screening exams, and other data elements presents an opportunity to 
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rely less on confirmed diagnoses from purely administrative sources. The ability to use 
documented clinical data may be particularly important for identification of racial/ethnic 
minorities in whom differences in stigma attached to AD/ADRD and beliefs about 
cognitive loss as a normal part of aging may contribute to lower rates of formal 
diagnosis.4, 20-23 Despite major gaps in consistent assessment of AD/ADRD, significant 
advancements have been made by changing data collection strategies from reliance on 
one data source to using combinations of EHR, claims, survey, and other data.  
 
By combining different data types and sources, validated data combinations, called 
“computable phenotypes” in informatics, can be created for more sensitive and reliable 
assessments of AD/ADRD status. Barnes et al24 describe eRADAR, a high-performing 
algorithm (that uses common EHR data to identify patients with undiagnosed dementia. 
The eMERGE consortium has a public computable phenotype to identify people visits 
for dementia-related diagnosis or prescriptions for dementia-related drugs.25 In other 
recent work, McCoy et al applied a validated natural language processing (NLP) tool to 
examine the association of cognitive symptoms with incident dementia diagnosis using 
longitudinal EHRs,26 and Beltrami et al27 used NLP to identify early linguistic signs of 
cognitive decline, not necessarily dementia itself, in a population of older adults.27 In 
addition, a large database of multimedia interactions and transcripts, DementiaBank,28 
is available for the study of communication in dementia patients, and has been used to 
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study natural language processing  techniques to classify and analyze the linguistic 
characteristics of AD patients.29-31 
 
Despite these exciting developments in use of EHR data for identifying PLWD, there are 
a number of critical issues left to address. It is imperative that investigators using their 
own “computable phenotype” to identify PLWD in a healthcare system validate and 
share their approaches. Investigators who opt to use an existing validated computable 
phenotype can both shorten development time and provide measures of accuracy for 
further validation in this growing field. Several online resources are available, including 
the Phenotype Knowledge Base (PheKB, phekb.org); via PhenX, a curated resource for 
research-specific definitions; and via the NIH Clinical Data Elements database, among 
others. Sharing the definitions used in ePCTs via open source, online resources can 
help continue to improve the quality and transferability of future trials. 
 
Several cautionary issues pertaining to use of EHR data in conducting ePCTs in PLWD 
are worth noting. It is important for investigators to be aware of poor or uneven data 
quality that continues to exist in EHRs. Even previously validated definitions and 
algorithms for identifying AD/ADRD populations and assessing their outcomes must be 
validated locally in each healthcare system to account for variations across settings and 
purposes. When data quality issues are discovered, it may be possible to mitigate them 
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by combining with other data, using advanced statistical approaches such as 
imputation, or by performing sensitivity analyses. In addition, there are tradeoffs to 
consider when choosing which healthcare generated data source to use. While EHR 
data are timely, their completeness and accuracy are variable. In addition, algorithms 
identifying PLWD suffer from potential biases, such as lower accuracy in minority 
populations and those with lower healthcare access. On the other hand, Medicare 
claims data may be less timely and have lower sensitivity for early disease, but are 
simpler to implement, have a reasonable evidence-base in terms of validation, and 
minimal missing data.  
 
Case studies – METRIcAL & PROVEN Trials  
 
We provide two case studies of ePCTs in nursing homes for patients with advanced 
dementia that use administrative data and EHR data to highlight the advantages and 
potential limits of using the pragmatic healthcare data approach. While using similar 
data sources, the differing aims of each study highlight how the degree of pragmatism 
that can be achieved varies and the importance of piloting the planned data strategy to 
assess its fitness for the intended use in the trial.  
 
This article is protected by copyright. All rights reserved.
Music & MEmory: A Pragmatic TRIal for Nursing Home Residents with 
ALzheimer's Disease (METRIcAL) 
 
METRIcAL is an ePCT of a personalized music intervention for nursing home residents 
with dementia. Personalized music is one of several sensory and reminiscence 
therapies being explored as low-risk alternatives to pharmaceutical approaches in 
managing behavioral and psychological symptoms of dementia.32 In METRIcAL, nursing 
home staff identify music a resident preferred when s/he was younger and deliver the 
music at early signs of agitation. The primary aim of METRIcAL is to determine whether 
or not personalized music reduces agitation among residents with advanced dementia 
compared to usual care. The pilot phase of METRIcAL was completed in 2018. The 
ePCT is currently underway; 81 NHs from four corporations are enrolled, 27 NHs 
receive the intervention in each study year (2019, 2020, 2021). 
 
PRagmatic trial of Video Education in NHs (PROVEN) 
 
PRagmatic trial Of Video Education in NHs (PROVEN) was an ePCT of a video to assist 
with advance care planning for nursing home residents with advanced dementia or 
advanced cardiopulmonary disease.33 This population was chosen because it is likely to 
experience unnecessary and non-beneficial care at the end of life, including multiple 
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hospital transfers. The primary outcome of interest was hospital transfers per person 
days alive. 360 NHs (intervention arm n=119; control arm n=241) within two NH 
healthcare systems were enrolled in the trial. Early results suggest the videos helped 
residents and their surrogates think differently about their medical choices and 
prompted conversations with a provider.34 
 
Data Use and Lessons Learned from METRIcAL and PROVEN Trials 
Both ePCTs benefitted from the routine collection of MDS assessments which contain 
diagnosis and cognitive and physical function for all nursing home residents. MDS was 
used to identify residents who had been in the nursing home at least 90 of the last 100 
days and who had a dementia diagnosis. The PROVEN intervention was delivered as a 
quality improvement intervention to everyone in the nursing home during the study 
period, so nursing home staff did not need to be aware of which residents were targeted 
for outcome analyses. This highly pragmatic approach was not possible in METRIcAL in 
which a subset of eligible residents were targeted to receive the intervention because of 
its resource intensive nature, requiring equipment (mp3 players, headphones, etc.) and 
staff effort in personalizing music selection. An onsite formal process for selecting study 
targets from potentially eligible residents identified in MDS was necessary in treatment 
and control nursing homes. 
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A second important use of healthcare data in both ePCTs was to measure the main 
outcome, hospital transfers using Medicare claims data for PROVEN and occurrence of 
agitated behaviors assessed in MDS for METRIcAL.  The PROVEN trial approach was 
straightforward; claims data allowed for complete case ascertainment because 
participants were all in Medicare and hospitals uniformly submit bills for admission. For 
METRIcAL, the main outcome of agitated behavior collected through MDS is dependent 
on recognition and documentation of the behaviors by nursing staff. During the pilot 
phase of METRIcAL, investigators discovered that agitated behaviors were under-
detected in MDS, likely due to staff normalization of those behaviors over time.35 The 
measurement strategy for the full-scale ePCT was adjusted to include on-site data 
collection for a randomly selected subset of participants.36 
 
In the design and pilot phase, both trials used what they observed in administrative data 
about their main outcome measures to address imbalances across sites that could be 
addressed by altering their randomization protocols. In METRIcAL, based on observed 
variation in documentation of agitated behaviors across nursing homes and the process 
for selecting eligible residents, study arms were balanced on behaviors and number of 
potentially eligible residents prior to randomization. Similarly, in PROVEN, trial arms 
were purposefully balanced at baseline on their historical rate of hospital transfers 
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(primary outcome) to address the high underlying variation in the rate of hospitalization 
across nursing homes.  
Finally, both PROVEN and the pilot phase of METRIcAL inserted new fields into the 
EHR to capture implementation adherence. The customized report integrated into the 
EHR to capture implementation adherence with the ePCT was underused and disliked 
by front-line providers, for whom the report had no relevance to clinical care.37 When 
planning an ePCT, researchers should use caution when inserting new elements into a 
workflow that do not serve a clinical purpose evident to front-line providers. 
 
These two recent ePCTs conducted in nursing homes illustrate how routinely collected 
administrative data can be leveraged to promote balanced randomized clusters, 
streamline NH recruitment, facilitate patient selection, and enable an efficient, pragmatic 
approach to outcome ascertainment. However, the data strategy can introduce new 
challenges and like many aspects of conducting a clinical trial benefit from pilot testing. 
 
Access, Protection and Sharing of Data  
Investigators need to initiate plans for accessing healthcare data early and plan for a 
lengthy process of gaining approvals and developing partnerships. Obtaining 
administrative data from federal sources, such as CMS, has a well-defined but lengthy 
process managed by ResDAC (https://www.resdac.org). Obtaining data directly from 
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health systems is attractive, but healthcare systems may not be familiar with Health 
Insurance Portability and Accountability Act (HIPAA) Privacy Rule as it pertains to 
research and may find the regulatory process daunting. Even when willing, it can take 
months or years to enter into the appropriate arrangements if healthcare systems are 
unfamiliar with the process.  
 
The use of EHR and other administrative data within ePCT designs, coupled with a 
focus on PLWD, require researchers to consider their data privacy and sharing options 
very carefully. Traditional efficacy trials typically obtain informed consent that includes 
explicit assurances to protect privacy and also authorizes plans for data-sharing 
covering future use. In fact, the NIH has proposed an expansion of data sharing rules 
for funded research.38 When ePCTs use data generated through the delivery of 
healthcare that is in the possession of providers, delivery systems, and payers, there 
are additional considerations: 1) data obtained with waiver of consent, especially for 
system-level interventions or cluster randomized trials, precludes specific consent for 
data sharing; 2) data volume and content include a large number of data points making 
deidentification of individuals difficult, perhaps impossible;39 and 3) providers, delivery 
systems, and payers may not agree to participate if data about their organization can be 
used for unspecified secondary purposes (Simon et al, 2015).39 In many cases, the 
ability to share individual data may ultimately be limited and researchers should be able 
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to provide a detailed description of the steps they took in obtaining their data that 




Data available through normal delivery of care to PLWD within healthcare system 
present tremendous opportunities to strengthen the design and conduct of AD/ADRD 
ePCTs. However, as this field is both complex and relatively nascent, novel 
methodologies and approaches must proceed thoughtfully and rigorously. Under the 
leadership of the Technical Data Core, the IMPACT Collaboratory will help advance our 
ability to conduct successful ePCTs that can improve care for PLWD by supporting 
investigators’ efforts to use healthcare-generated data. The Core will help devise 
approaches to overcoming some of the barriers associated with using data obtained in 
the course of care by: 1) connecting investigators to validated algorithms for identifying 
PLWD and contributing to creating them where they do not exist; 2) finding and 
developing measures for outcomes important to stakeholders, including PLWD, 
caregivers and health systems; and 3) generating information to help investigators find 
settings and healthcare system partners whose characteristics and populations served 
are well aligned with the study’s aims.  
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Figure 1: Overview of Uses of Administrative or EHR data in Embedded Pragmatic 
Clinical Trials 
 
Table 1: Healthcare Generated Data Types, their Content, Examples of Potential Uses 
and the Sources Employed  
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Table 1: Healthcare Generated Data Types, their Content, Examples of Potential Uses 
and the Sources Employed  
Data Type Information 
contained in data 
type 
Examples of Possible 
Use 
Example Sources 
for Data Type 
Claims Data Inpatient, clinic, 
home health, 
hospice, medication 
data used for billing 
Identify participants 
diagnosed with 
dementia;                                        







































Clinical data  for 
quality reporting & 
payment in nursing 
homes and home 
care 
 Identify home health 
agencies or nursing 





health) from CMS or 
directly from 
healthcare setting. 





(labs, problem lists), 
text fields, billing 
data, patient 
reported outcomes 
Cognitive screens & 








Provider Files Type, size, location, 
ownership 
Find physician practices 
serving high ethnic 
minority populations 
PECOS, Provider of 
Service Files,  
Medicare Provider 
Practice & Specialty 
Key: VRDC = Virtual Research Data Center; DRN = Distributed Research Network, 
PECOS = Medicare Provider Enrollment, Chain, & Ownership System; POS= Medicare 
Place of Service File; 
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